Consensus Daxor Corporation

Equities

DXR

US2394671034

End-of-day quote Nasdaq Other stock markets 06:00:00 2024-05-12 pm EDT			5-day change	1st Jan Change
9.4 ^USD	-1.60%		-4.08%	-2.08%

Apr. 16	Daxor Corporation Announces Two New Studies Validating the Clinical Benefits of Daxor?s Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion	CI
Apr. 10	Daxor Corporation Announces New Hospital Account at Leading Chicago Hospital	CI

Evolution of the average Target Price on Daxor Corporation

Price target over the last 5 years

History of analyst recommendation changes

45a28f611d39947bfcf60266ec8da395.PyMMYzXu9zUtkYzoPzczpmVSsEwYkzqTWsODaqdbiU4.d0pLNGacgFRf3b-ZCQVrylE8xnUg_m3CLYTzX-Ud5DgLEz4gca-PW1nm-w~f3dea263ca1b60e7492f049d9506b098

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

9.4 USD

Average target price

23.25 USD

Spread / Average Target

+147.34%

High Price Target

24.5 USD

Spread / Highest target

+160.64%

Low Price Target

22 USD

Spread / Lowest Target

+134.04%

Consensus detail

Consensus revision (last 18 months)

Chiffre d''affaires - Rate of surprise

Company calendar